All News

Found 237 articles

• Aragen Acquires Intox Pvt. Ltd.

  12/15/2021

  Aragen Life Sciences, a global research, development, and manufacturing solutions provider, announced that it has signed a definitive agreement to acquire Pune-based Intox Pvt. Ltd.

• Mindset Pharma to Participate in Citi’s Psychedelic Drug Call Series on January 6th

  12/15/2021

  Mindset Pharma Inc. today announced that it will participate in Citi’s Psychedelic Drug Call Series to be held virtually on Thursday, January 6, 2022.   

• AION Labs, Powered by BioMed X, Launches Second Global Call for Application: Artificial Intelligence for Clinical Trial Readiness of Drug Candidates

  12/13/2021

  AION Labs, a first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced today the launch of the second global call for application to identify biomedical scientists and inventors to form a new startup at AION Labs' headquarters in Rehovot, Israel.

• Mindset Pharma to Participate in Stifel GMP’s The Future of Healthcare Conference on December 8th

  12/2/2021

  Mindset Pharma Inc. today announced that it will participate in Stifel GMP’s The Future of Healthcare Conference to be held virtually on Wednesday, December 8, 2021.

• Mindset to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th

  11/29/2021

  Mindset Pharma Inc. today announced that it will participate in the H.C. Wainwright 2 nd Annual Psychedelics Conference to be hosted virtually on Monday, December 6, 2021.

• Recro Reports Third Quarter 2021 Financial Results

  11/9/2021

  Recro Pharma, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, reported financial results for the third quarter and nine months ended September 30, 2021.

• Mindset Pharma Announces Poster Presentation of Preclinical Data for Benchmarking Next-Generation Psychedelics at Neuroscience 2021

  11/8/2021

  Mindset Pharma Inc. today announced a poster presentation of preclinical benchmarking data for the Company’s optimized psilocybin analog, MSP-1014

• Aragen expects to ride wave of US biotech growth in 2022 – influx of discovery capital is surging demand for CDMO services

  11/5/2021

  The company, states growth is being predominantly driven by biotech partners with innovative products, particularly those in the United States where outsourcing demand is growing quickly.

• MD&M East Announces 2021 Keynote and Speaker Lineup Set to Deliver Technical and Forward-looking Insights Impacting Medical Device Manufacturers

  11/4/2021

  Medical Design & Manufacturing today announced all-new programming for the 2021 edition, taking place from December 7 through 9 at the Jacob Javits Convention Center.

• Mindset Pharma to Participate in Wonderland: Miami on November 8-9, 2021

  10/26/2021

  Mindset Pharma Inc. today announced that it will participate in Microdose’s Wonderland: Miami to be held at the Adrienne Arsht Center for the Performing Arts in Miami, FL on November 8-9

• Mindset Pharma Reports Fiscal Year 2021 Financial Results and Provides Corporate Update

  10/26/2021

  Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today provided a corporate update and reported financial results for its fiscal year ended June 30, 2021.

• Urovant Sciences Announces Leadership Appointments to Drive Future Growth and Geographic Expansion

  10/18/2021

  Laura Genatossio Appointed Senior Vice President and General Manager, Europe Alana Darden Powell Promoted to Vice President, Corporate Communications Mark Niemaszek Named Senior Vice President, Corporate Planning Ted Chan Promoted to Senior Vice President, Associate General Counsel and Head of Intellectual Property

• Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the COPE Program with InterVivo Solutions

  10/14/2021

  Mindset Pharma Inc. today announced that, under its Co-operative Psychedelics Evaluation Platform (“COPE”) program with InterVivo Solutions (“InterVivo”), the Company has further developed its first generation psychedelics benchmarking data by establishing standard pharmacokinetic, brain penetration, and drug discrimination data and protocols across LSD, psilocybin, and 5-MeO-DMT.

• Alveron Pharma BV raises a further EUR 3.9 million to progress first in class drug to treat life-threatening anticoagulant-related bleeds

  10/11/2021

  Alveron Pharma BV (Nijmegen, The Netherlands) has raised a further EUR 3.9 million to fund the continued development of OKL-1111, a first-in-class drug to treat anticoagulant related bleeds.

• KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

  10/11/2021

  Virtual Investor Conferences  in partnership with KCSA Strategic Communications  today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference.

• Mindset Pharma to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th

  10/6/2021

   Mindset Pharma Inc. today announced that James Lanthier , CEO of Mindset, will participate in the KCSA Psychedelics Investor Conference to be held at VirtualInvestorConferences.com on October 13-14, 2021.

• Mindset Pharma Expands Pipeline: Identifies Additional Next Generation 5-MeO-DMT-Inspired Lead CandidatesPreclinical data demonstrated efficacy and an improved safety profile of MSP-4019 and MSP-4020 in head-to-head comparisons against 5-MeO-DMT

  9/29/2021

  Mindset Pharma Inc. today announced that, in addition to its potential lead new chemical entity (“NCE”) candidate, MSP-4018, the Company has identified two additional pipeline opportunities from its Family 4 compounds, MSP-4019 and MSP-4020.

• Mindset Pharma Announces Inclusion in NYSE Listed AdvisorShares Psychedelics Exchange Traded Fund (ETF)

  9/23/2021

  Mindset Pharma Inc. today announced that it has been included in the AdvisorShares Psychedelics ETF traded on the NYSE Arca under the ticker symbol “PSIL.”

• Actinium Announces Multiple Senior Leadership Appointments Including Chief Business and Commercial Officer, New Chief Medical Officer and Vice President, Patent and Legal Counsel

  9/23/2021

  Actinium Pharmaceuticals, Inc. announced multiple senior leadership appointments including Arun Swaminathan, Ph.D., as Chief Business and Commercial Officer, Paul Diamond, Ph.D., as Vice President, Patent and Legal Counsel and Avinash Desai, M.D., who previously served as Executive Vice President, Clinical Development, Operations and Medical Affairs, to the position of Chief Medical Officer, effective immediately.

• Mindset Pharma Announces Further Preclinical Results Demonstrating Strong Efficacy and Improved Safety Profile for its 5-MeO-DMT-Inspired Drug Candidate, MSP-4018

  9/20/2021

  Mindset Pharma Inc. today announced that preclinical proof-of-concept data comparing its clinical candidate, MSP-4018, against 5-MeO-DMT